



SVF Vaccines appoints Raheleh Nassaji as Chief Executive Officer to lead transition into Phase I clinical development

Stockholm, Sweden, 10 February 2026. SVF Vaccines AB (“SVF Vaccines” or the “Company”), a Swedish biotechnology company developing vaccines and immunotherapies for serious infectious diseases, today announced the appointment of Raheleh Nassaji as Chief Executive Officer (CEO).

The appointment comes at a key moment for the Company as SVF Vaccines progresses towards first-in-human Phase I clinical development of its lead program in chronic viral hepatitis B and D while continuing preparations for upcoming financing, strategic partnerships, and broader corporate transformation initiatives.

Raheleh Nassaji brings nearly two decades of international experience across big pharma, biotech and healthcare innovation. She combines scientific depth with strong strategic leadership in clinical development planning, capital strategy and business development.

Most recently, Raheleh served as Vice President Corporate & Business Development at Hansa Biopharma, where she played a key role in shaping corporate strategy, investor communication, valuation work and capital planning, and led partnership initiatives spanning clinical development and commercialization. Prior to that, she held senior positions at Pfizer, leading international commercial and strategic initiatives across the Emerging Markets organization. Her experience spans biologics, vaccines, immunomodulation and infectious diseases, with a strong focus on translating scientific innovation into scalable development programs and long-term value creation.

“SVF Vaccines is at an important inflection point,” said Raheleh Nassaji, CEO of SVF Vaccines. “The strength of the science and the opportunity to advance the company’s lead programs into the clinic were key reasons I was drawn to this role. My focus will be on disciplined clinical execution, building a strong financing and partnering strategy, and positioning the company for long-term value creation as we generate early clinical data.”

John Öhd, Chair of the Board of Directors of SVF Vaccines, added: “We are honored to welcome Raheleh Nassaji who brings a unique combination of biomedical science training from Karolinska Institutet and business expertise from the Stockholm School of Economics. Her deep scientific understanding, paired with a proven track record of



strategic and commercial leadership in clinical-stage biotech, capital strategy and global partnerships makes her exceptionally well suited to lead SVF Vaccines into its next phase.”

For further information, please contact:

Raheleh Nassaji, Chief Executive Officer, SVF Vaccines AB

Phone: +46 (0) 76 495 12 85, e-mail: raheleh.nassaji@svfvaccines.com

John Öhd, Chairman of the Board, SVF Vaccines AB

Phone: +46 (0) 70 766 80 97, e-mail: john.ohd@karolinskadevelopment.com

About SVF Vaccines

SVF Vaccines AB is a Swedish biotechnology company developing vaccines and immunotherapies for serious infectious diseases, based on proprietary technology originating from research at Karolinska Institutet. The Company’s portfolio includes a lead program targeting chronic hepatitis D, as well as earlier-stage programs in additional high-need viral indications. SVF Vaccines aims to advance its pipeline through focused clinical development and collaborations with academic and strategic partners.